Dr. Reddy’s Laboratories Ltd ADR (RDY)
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Dr. Reddy’s Laboratories Ltd ADR is a Healthcare company with a market capitalization of $12.81B, a trailing P/E ratio of 28.5, and a dividend yield of 0.54%.
5-Year Price History
Latest Annual Financials · FY ending March 31, 2026 · in INR
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q4 2026 | May 11, 2026 | $0.00 | $0.16 | -100.0% |
| Q3 2025 | January 20, 2026 | $0.16 | $0.16 | +1.9% |
| Q2 2025 | October 24, 2025 | $0.20 | $18.31 | -98.9% |
| Q1 2025 | July 23, 2025 | $17.02 | $0.21 | +8004.8% |
| Q4 2025 | May 9, 2025 | $19.11 | $17.13 | +11.6% |
| Q3 2024 | January 29, 2025 | $16.94 | $16.15 | +4.9% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is Dr. Reddy’s Laboratories Ltd ADR's market cap?
As of June 29, 2026, Dr. Reddy’s Laboratories Ltd ADR (RDY) has a market capitalization of $12.81B.
What is Dr. Reddy’s Laboratories Ltd ADR's P/E ratio?
Dr. Reddy’s Laboratories Ltd ADR trades at a trailing price-to-earnings (P/E) ratio of 28.5. Its forward P/E is 28.5.
Does Dr. Reddy’s Laboratories Ltd ADR pay a dividend?
Yes — Dr. Reddy’s Laboratories Ltd ADR pays a dividend yielding 0.54%, an annual payout of $8.00 per share.
What sector is RDY in?
Dr. Reddy’s Laboratories Ltd ADR is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What was Dr. Reddy’s Laboratories Ltd ADR's revenue?
In its latest reported fiscal year (ending March 31, 2026), Dr. Reddy’s Laboratories Ltd ADR reported revenue of 353.47B INR and net income of 45.09B INR.
Ask your own questions about RDY
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.